Company’s 36-month beta value is 0.35.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BFRI is 8.07M, and currently, short sellers hold a 4.38% ratio of that floaft. The average trading volume of BFRI on July 01, 2025 was 143.56K shares.
BFRI) stock’s latest price update
Biofrontera Inc (NASDAQ: BFRI) has seen a rise in its stock price by 18.27 in relation to its previous close of 0.6. However, the company has experienced a 12.94% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-30 that Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG. Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% – 35% of net sales.
BFRI’s Market Performance
BFRI’s stock has risen by 12.94% in the past week, with a monthly rise of 16.60% and a quarterly drop of -12.48%. The volatility ratio for the week is 10.44% while the volatility levels for the last 30 days are 9.97% for Biofrontera Inc The simple moving average for the last 20 days is 12.74% for BFRI stock, with a simple moving average of -22.42% for the last 200 days.
BFRI Trading at 4.87% from the 50-Day Moving Average
After a stumble in the market that brought BFRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.95% of loss for the given period.
Stock Fundamentals for BFRI
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.55 for the gross margin
The net margin for Biofrontera Inc stands at -0.3. The total capital return value is set at -2.89. Equity return is now at value -384.98, with -56.00 for asset returns.
Based on Biofrontera Inc (BFRI), the company’s capital structure generated 0.91 points at debt to capital in total, while cash flow to debt ratio is standing at -2.27. The debt to equity ratio resting at 10.37. The interest coverage ratio of the stock is 4.57.
Currently, EBITDA for the company is -14.44 million with net debt to EBITDA at -0.2. When we switch over and look at the enterprise to sales, we see a ratio of 0.26. The receivables turnover for the company is 9.42for trailing twelve months and the total asset turnover is 2.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
In a nutshell, Biofrontera Inc (BFRI) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
